Leonardo Roa

Leonardo Roa

Auto-generated profile, based on publicly available information

Leonardo Roa

Animal Science Faculty, Universidad de Ciencias Aplicadas y Ambientales (UDCA), Bogotá D.C., 111166, Colombia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2022 in Preventive Veterinary Medicine
Verified
Journal Article
Closed access
ARAlejandra Ruiz-Laiton
Alejandra Ruiz-Laiton
NMNorela Molano-Ayala
Norela Molano-Ayala
SGSebastián García-Castiblanco
Sebastián García-Castiblanco
APAngie Melissa Puentes-Orozco
Angie Melissa Puentes-Orozco
AFAna Carolina Falla
Ana Carolina Falla
CACatalina Avendaño
Catalina Avendaño

2 June 2020 in Revista Mexicana de Ciencias Pecuarias
Verified
Journal Article
Open access
PDF file
CCCarmen Celis
Carmen Celis
DODiego Ordóñez
Diego Ordóñez
LRLeonardo Roa
Leonardo Roa
SCSergio Andrei Cuervo-Escobar
Sergio Andrei Cuervo-Escobar
DGDajane Garzón-Rodríguez
Dajane Garzón-Rodríguez
LMLuisa Fernanda Merchán
Luisa Fernanda Merchán
Preliminary study of ivermectin residues in bovine livers in the Bogota Savanna

30 December 2019 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
JLJennifer Lambraño
Jennifer Lambraño
HCHernando Curtidor
Hernando Curtidor
CACatalina Avendaño
Catalina Avendaño
DDDiana Díaz-Arévalo
Diana Díaz-Arévalo
LRLeonardo Roa
Leonardo Roa
MPManuel Alfonso Patarroyo
Manuel Alfonso Patarroyo
Malaria continues being a high-impact disease regarding public health worldwide; the WHO report for malaria in 2018 estimated that ~219 million cases occurred in 2017, mostly caused by the parasite Plasmodium falciparum. The disease cost the lives of more than 400,000 people, mainly in Africa. In spite of great efforts aimed at developing better prevention (i.e., a highly effective vaccine), diagnosis, and treatment methods for malaria, no efficient solution to this disease has been advanced to date. The Fundación Instituto de Inmunología de Colombia (FIDIC) has been developing studies aimed at furthering the search for vaccine candidates for controlling P. falciparum malaria. However, vaccine development involves safety and immunogenicity studies regarding their formulation in animal models before proceeding to clinical studies. The present work has thus been aimed at evaluating the safety and immunogenicity of a mixture of 23 chemically synthesised, modified peptides (immune protection-inducing protein structure (IMPIPS)) derived from different P. falciparum proteins. Single and repeat dose assays were thus used with male and female BALB/c mice which were immunised with the IMPIPS mixture. It was found that single and repeat dose immunisation with the IMPIPS mixture was safe, both locally and systemically. It was observed that the antibodies so stimulated recognised the parasite’s native proteins and inhibited merozoite invasion of red blood cells in vitro when evaluating the humoral immune response induced by the IMPIPS mixture. Such results suggested that the IMPIPS peptide mixture could be a safe candidate to be tested during the next stage involved in developing an antimalarial vaccine, evaluating local safety, immunogenicity, and protection in a nonhuman primate model.